Project description
Artificial intelligence for diabetes treatment
Diabetes is a chronic metabolic disease that causes serious health complications affecting millions of people and children worldwide. Diabetes requires long-term care treatment from a specialists and patient self-management on a daily basis. Patients’ health has improved with the use of mobile phone applications. However, there is need to identify a clinically relevant app amongst the thousands available in the market. The EU-funded DIABETESMART project proposes a mobile platform for daily diabetes management. The platform is clinically validated at Class IIA and compliant with Europe’s new Medical Device Regulation. It is powered by artificial intelligence, providing individual lifestyle-based and country context-based tailored recommendations. The innovation integrates the user’s blood medical device and wearable of choice, allowing patients to live a normal life.
Objective
Diabetes mellitus, a common chronic disease that is associated with high blood glucose (also called blood sugar) can lead to potentially fatal health complications. Globally, 415 million people were diagnosed with diabetes in 2015, estimated to reach 642 million by 2040. In Europe disease prevalence is high, 66 million people were diagnosed in 2017, estimate to reach 81 million people by 2045, with 28,200 children (bellow 19 years old) diagnosed each year. Diabetes requires long-life care management from a physician care team and patient daily self-management. Improvement of diabetes self-care was shown when people with diabetes used mobile phone application. Yet, the challenge is to identify a clinical relevant App between the thousand diabetes management applications available in the market. Hedia, a Danish pioneer start-up company was founded with the mission to make life easier for people with diabetes. Based on the current challenges, we have developed a mobile platform for the daily diabetes management that outperforms the current stat-of-the-art: clinically validated Class IIA compliant to Europes’s new MDR; an artificial intelligent powered that provides tailored recommendations based on the individuals lifestyle and country context; integrate the user’s blood medical device and wearable of choice and other advanced features that enable people with diabetes live a normal life.
DIABETESMART project targets the diabetes care market, which has an estimate value of €69.10B in 2016, forecast to reach €137.28B by 2022 with a 12.4% CAGR (2016-2022). We aim to offer DIABETESMART to corporates -who will obtain further revenues of €18M per year- and to people with diabetes who will benefit from real-time clinically meaningful insights based on AI by 2021. We foresee to reach revenues of €26.6 million with €75.1 million in cumulative profits and increase our team to at least 25 employees (from current 11) by 2026.
Fields of science
Not validated
Not validated
- medical and health sciencesclinical medicineendocrinologydiabetes
- engineering and technologyelectrical engineering, electronic engineering, information engineeringinformation engineeringtelecommunicationsmobile phones
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistancemultidrug resistance
Programme(s)
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
2200 KOBENHAVN
Denmark
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.